SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on November 14, 2002; DOI 10.1182/blood-2002-10-3014. This Article Full Text Full Text (PDF) Erratum (v102,p1950) All Versions of this Article: 2002-10-3014v1 101/7/2886    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Blaha, P. Articles by Wekerle, T. Search for Related Content PubMed PubMed Citation Articles by Blaha, P. Articles by Wekerle, T. Related Collections Immunobiology Transplantation Immunotherapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 April 2003, Vol. 101, No. 7, pp. 2886-2893 TRANSPLANTATION The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade Peter Blaha, Sinda Bigenzahn, Zvonimir Koporc, Maximilian Schmid, Felix Langer, Edgar Selzer, Helga Bergmeister, Friedrich Wrba, Josef Kurtz, Christopher Kiss, Erich Roth, Ferdinand Muehlbacher, Megan Sykes, and Thomas Wekerle From the Division of Transplantation, Department of Surgery; the Department of Radiotherapy and Radiobiology; the Institute of Biomedical Research; the Institute of Clinical Pathology; and the Surgical Research Laboratories, Vienna General Hospital, University of Vienna, Austria; and the Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston. We recently developed a murine protocol for the induction of allogeneic mixed chimerism and tolerance employing nonmyeloablative total body irradiation (TBI), standard-dose bone marrow transplantation (BMT), and costimulation blockade (cobl) with an anti-CD154 monoclonal antibody (mAb) plus CTLA4Ig. We now evaluated whether a short course (1 month) of immunosuppressive drugs, which would be ethically required in the clinical setting of organ transplantation to prevent graft loss in case tolerance is not achieved, interferes with tolerance induced with this regimen. Our results show that calcineurin inhibitors (cyclosporin A [CyA] or tacrolimus [FK]) inhibit development of long-term chimerism and abrogate tolerance induction in this model. Rapamycin (rapa), methylprednisolone (MP), FTY720, and mycophenolate mofetil (MMF), in contrast, have no negative effect on chimerism or tolerance development. Peripheral deletion of donor-reactive T cells, which usually occurs in the weeks following BMT in this model, is blocked by CyA and FK, but not by the other drugs tested. Furthermore, we found that the additional use of compatible immunosuppressive drugs (rapa plus MMF plus MP) allows the dose of TBI to be reduced, so that mixed chimerism and donor skin-graft acceptance can be achieved with 1 Gy using clinically feasible cell numbers. Thus, this protocol of BMT with costimulation blockade can be safely combined with a clinically tested immunosuppressive regimen to permit success with a lower dose of irradiation. These results should facilitate clinical application of this tolerance strategy. © 2003 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Tchorsh-Yutsis, G. Hecht, A. Aronovich, E. Shezen, Y. Klionsky, C. Rosen, R. Bitcover, S. Eventov-Friedman, H. Katchman, S. Cohen, et al. Pig Embryonic Pancreatic Tissue as a Source for Transplantation in Diabetes: Transient Treatment With Anti-LFA1, Anti-CD48, and FTY720 Enables Long-Term Graft Maintenance in Mice With Only Mild Ongoing Immunosuppression Diabetes, July 1, 2009; 58(7): 1585 - 1594. [Abstract] [Full Text] [PDF] H. R. Turnquist, T. L. Sumpter, A. Tsung, A. F. Zahorchak, A. Nakao, G. J. Nau, F. Y. Liew, D. A. Geller, and A. W. Thomson IL-1{beta}-Driven ST2L Expression Promotes Maturation Resistance in Rapamycin-Conditioned Dendritic Cells J. Immunol., July 1, 2008; 181(1): 62 - 72. [Abstract] [Full Text] [PDF] U. Baranyi, B. Linhart, N. Pilat, M. Gattringer, J. Bagley, F. Muehlbacher, J. Iacomini, R. Valenta, and T. Wekerle Tolerization of a Type I Allergic Immune Response through Transplantation of Genetically Modified Hematopoietic Stem Cells J. Immunol., June 15, 2008; 180(12): 8168 - 8175. [Abstract] [Full Text] [PDF] R. Zeiser, D. B. Leveson-Gower, E. A. Zambricki, N. Kambham, A. Beilhack, J. Loh, J.-Z. Hou, and R. S. Negrin Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells Blood, January 1, 2008; 111(1): 453 - 462. [Abstract] [Full Text] [PDF] Y.-H. Lee, Y.-R. Lee, S.-A Im, S.-I. Park, K.-H. Kim, T. Gerelchuluun, S. Song, K. Kim, and C.-K. Lee Calcineurin Inhibitors Block MHC-Restricted Antigen Presentation In Vivo J. Immunol., November 1, 2007; 179(9): 5711 - 5716. [Abstract] [Full Text] [PDF] A. Ramos-Barron, C. Pinera-Haces, C. Gomez-Alamillo, I. Santiuste-Torcida, J.C. Ruiz, L. Buelta-Carrillo, R. Merino, A.L.M. de Francisco, and M. Arias Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment Lupus, October 1, 2007; 16(10): 775 - 781. [Abstract] [PDF] R. Girlanda and A. D. Kirk Frontiers in Nephrology: Immune Tolerance to Allografts in Humans J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2242 - 2251. [Abstract] [Full Text] [PDF] H. R. Turnquist, G. Raimondi, A. F. Zahorchak, R. T. Fischer, Z. Wang, and A. W. Thomson Rapamycin-Conditioned Dendritic Cells Are Poor Stimulators of Allogeneic CD4+ T Cells, but Enrich for Antigen-Specific Foxp3+ T Regulatory Cells and Promote Organ Transplant Tolerance J. Immunol., June 1, 2007; 178(11): 7018 - 7031. [Abstract] [Full Text] [PDF] B. Linhart, S. Bigenzahn, A. Hartl, C. Lupinek, J. Thalhamer, R. Valenta, and T. Wekerle Costimulation Blockade Inhibits Allergic Sensitization but Does Not Affect Established Allergy in a Murine Model of Grass Pollen Allergy J. Immunol., March 15, 2007; 178(6): 3924 - 3931. [Abstract] [Full Text] [PDF] M. Noris, F. Casiraghi, M. Todeschini, P. Cravedi, D. Cugini, G. Monteferrante, S. Aiello, L. Cassis, E. Gotti, F. Gaspari, et al. Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs J. Am. Soc. Nephrol., March 1, 2007; 18(3): 1007 - 1018. [Abstract] [Full Text] [PDF] D. Valmori, V. Tosello, N. E. Souleimanian, E. Godefroy, L. Scotto, Y. Wang, and M. Ayyoub Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells J. Immunol., July 15, 2006; 177(2): 944 - 949. [Abstract] [Full Text] [PDF] R. Zeiser, V. H. Nguyen, A. Beilhack, M. Buess, S. Schulz, J. Baker, C. H. Contag, and R. S. Negrin Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production Blood, July 1, 2006; 108(1): 390 - 399. [Abstract] [Full Text] [PDF] M. Battaglia, A. Stabilini, E. Draghici, B. Migliavacca, S. Gregori, E. Bonifacio, and M.-G. Roncarolo Induction of Tolerance in Type 1 Diabetes via Both CD4+CD25+ T Regulatory Cells and T Regulatory Type 1 Cells Diabetes, June 1, 2006; 55(6): 1571 - 1580. [Abstract] [Full Text] [PDF] J. J. A. Coenen, H. J. P. M. Koenen, E. van Rijssen, L. B. Hilbrands, and I. Joosten Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells Blood, February 1, 2006; 107(3): 1018 - 1023. [Abstract] [Full Text] [PDF] M. Battaglia, A. Stabilini, E. Draghici, S. Gregori, C. Mocchetti, E. Bonifacio, and M.-G. Roncarolo Rapamycin and Interleukin-10 Treatment Induces T Regulatory Type 1 Cells That Mediate Antigen-Specific Transplantation Tolerance Diabetes, January 1, 2006; 55(1): 40 - 49. [Abstract] [Full Text] [PDF] C. Domenig, A. Sanchez-Fueyo, J. Kurtz, S. P. Alexopoulos, C. Mariat, M. Sykes, T. B. Strom, and X. X. Zheng Roles of Deletion and Regulation in Creating Mixed Chimerism and Allograft Tolerance Using a Nonlymphoablative Irradiation-Free Protocol J. Immunol., July 1, 2005; 175(1): 51 - 60. [Abstract] [Full Text] [PDF] M. Battaglia, A. Stabilini, and M.-G. Roncarolo Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells Blood, June 15, 2005; 105(12): 4743 - 4748. [Abstract] [Full Text] [PDF] M. Karim, G. Feng, K. J. Wood, and A. R. Bushell CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation Blood, June 15, 2005; 105(12): 4871 - 4877. [Abstract] [Full Text] [PDF] S. Vignot, S. Faivre, D. Aguirre, and E. Raymond mTOR-targeted therapy of cancer with rapamycin derivatives Ann. Onc., April 1, 2005; 16(4): 525 - 537. [Abstract] [Full Text] [PDF] A Davidson, B Diamond, D Wofsy, and D Daikh Block and tackle: CTLA4Ig takes on lupus Lupus, March 1, 2005; 14(3): 197 - 203. [Abstract] [PDF] B. Metzler, P. Gfeller, M. Bigaud, J. Li, G. Wieczorek, C. Heusser, P. Lake, and A. Katopodis Combinations of Anti-LFA-1, Everolimus, Anti-CD40 Ligand, and Allogeneic Bone Marrow Induce Central Transplantation Tolerance through Hemopoietic Chimerism, Including Protection from Chronic Heart Allograft Rejection J. Immunol., December 1, 2004; 173(11): 7025 - 7036. [Abstract] [Full Text] [PDF] T. Kimura, A. M. Boehmler, G. Seitz, S. Kuci, T. Wiesner, V. Brinkmann, L. Kanz, and R. Mohle The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells Blood, June 15, 2004; 103(12): 4478 - 4486. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020